Neve Rachael L
Department of Psychiatry, Harvard Medical School, MRC 223, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA.
Trends Neurosci. 2003 Sep;26(9):461-3. doi: 10.1016/s0166-2236(03)00231-5.
Modulation of the proteases that process the amyloid precursor protein (APP) is a major therapeutic strategy for the treatment and prevention of Alzheimer's disease (AD). The discovery of a novel endogenous modulator of alpha-secretase-mediated, in preference to beta-secretase-mediated, cleavage of APP implicates sumoylation in the etiology of AD, and offers a new therapeutic target for intervention in APP processing.